Evidence map›Paper›PMID 38046670›Full record

ArticleFrontiers in cell and developmental biology2023

Phenotype plasticity and altered sensitivity to chemotherapeutic agents in aggressive prostate cancer cells.

Allan I Paxson, Loren H Chang, Jaime M C Gard, William L Harryman, Colin S Nelson, Stella B Salmon, Kendra D Marr, Leah M Wachsmuth, Anita Ramanathan, Jing Ran and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Allan I PaxsonPartnership for Native American Cancer Prevention, University of Arizona, Tucson, AZ, United States.
Loren H ChangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Jaime M C GardUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
William L HarrymanUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
Colin S NelsonUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
Stella B SalmonUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
Kendra D MarrUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
Leah M WachsmuthNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Anita RamanathanNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Jing RanNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Abhijeet KapoorNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Juan J MaruganNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Mark J HendersonNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Tino W SanchezNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Anne E CressUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
University of Arizona · USNational Center for Advancing Translational Sciences · USNational Institutes of Health · USUniversity of Arizona Cancer Center

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
Training/Career Development and Education Core and PlansU54CA143925 · NCI · NORTHERN ARIZONA UNIVERSITY · PI Jason A Wilder · 2009 to 2026
$27.5M
Uranium as an Environmental Risk Factor for Cancer Among the NavajoU54CA143924 · NCI · UNIVERSITY OF ARIZONA · PI Jennifer Wright Bea · 2009 to 2026
$26.7M
Human Prostate Cancer Metastasis and Laminin Binding IntegrinsR01CA159406 · NCI · UNIVERSITY OF ARIZONA · PI CRESS, ANNE E · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA159406NCI NIH HHS U54 CA143924NCI NIH HHS U54 CA143925
6 · The paper itself

Abstract

In 2023, approximately 288,300 new diagnoses of prostate cancer will occur, with 34,700 disease-related deaths. Death from prostate cancer is associated with metastasis, enabled by progression of tumor phenotypes and successful extracapsular extension to reach Batson's venous plexus, a specific route to the spine and brain. Using a mouse-human tumor xenograft model, we isolated an aggressive muscle invasive cell population of prostate cancer, called DU145

Indexed as

aggressivecell viabilitychemoresistanceprostate cancersensitivity

Identifiers

PMID38046670
PMCPMC10690371
OpenAlexW4388721478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.